share_log

Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $60

Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $60

奥本海默维持Corbus Pharmicals的跑赢大盘,将目标股价上调至60美元
Benzinga ·  05/08 11:54

Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $58 to $60.

奥本海默分析师杰夫·琼斯维持科布斯制药公司(纳斯达克股票代码:CRBP)的表现跑赢大盘,并将目标股价从58美元上调至60美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发